Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938687 | 0.94 | KDM4E (0.67) | KDM4ERXFP1P2RX3MKNK1 | |
| SCHEMBL938917 | 0.93 | KDM4E (0.64) | KDM4ERXFP1P2RX3MKNK1 | |
| SCHEMBL940621 | 0.92 | KDM4E (0.63) | KDM4ERXFP1P2RX3MKNK1 | |
| SCHEMBL18000062 | 0.90 | KDM4E (0.61) | KDM4ERXFP1P2RX3MKNK1 | |
| SCHEMBL969115 | 0.86 | KDM4E (1.00) | KDM4ERXFP1 | |
| SCHEMBL939224 | 0.83 | KDM4E (0.72) | KDM4ERXFP1P2RX3 | |
| SCHEMBL24996003 | 0.81 | MKNK1 (0.66) | P2RX3MKNK1 | |
| SCHEMBL30879369 | 0.81 | MKNK1 (0.66) | P2RX3MKNK1 | |
| SCHEMBL18358077 | 0.80 | P2RX3 (0.66) | RXFP1P2RX3MKNK1 | |
| SCHEMBL13473581 | 0.80 | KDM4E (0.64) | KDM4ERXFP1P2RX3MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182489-A1 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-06-06 | — | — | US | disclosed |
| WO-2024048809-A1 | HETEROARYL DERIVATIVE CONTAINING N, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 보로노이 주식회사 | 2024-03-07 | — | — | WO | disclosed |
| EP-4308574-A1 | NEW 5,6,7,8-TETRAHYDROPYRIDO[4',3':4,5] THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-01-24 | — | — | EP | disclosed |
| US-11578080-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| WO-2022195022-A1 | NEW 5,6,7,8-TETRAHYDROPYRIDO[4',3':4,5] THIENO[2,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-09-22 | — | — | WO | disclosed |
| US-20210395267-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11136336-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| WO-2021074197-A1 | THIENOPYRIMIDONES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210107918-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107919-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2010054285-A2 | FUSED BICYCLIC AND TRICYCLIC PYRIMIDINE COMPOUNDS AS TYROSINE KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054285-A2 | FUSED BICYCLIC AND TRICYCLIC PYRIMIDINE COMPOUNDS AS TYROSINE KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182489-A1 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | KDM4E 3954/4885RXFP1 975/4885P2RX3 14/4885 |
| US-11578080-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | KDM4E 3740/4885RXFP1 1972/4885P2RX3 29/4885 |
| US-20210107918-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | KDM4E 3563/4885RXFP1 1986/4885P2RX3 32/4885 |
| US-20210107919-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | KDM4E 3563/4885RXFP1 1986/4885P2RX3 32/4885 |
| US-20210395267-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | KDM4E 3563/4885RXFP1 1986/4885P2RX3 32/4885 |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | DPYD, TYMP, TPMT | KDM4E 1879/4885RXFP1 4870/4885P2RX3 360/4885 |
| US-11136336-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | KDM4E 3740/4885RXFP1 1972/4885P2RX3 29/4885 |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | ERBB2, EGFR, BMX | KDM4E 2452/4885RXFP1 4207/4885P2RX3 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.